48. 原発性抗リン脂質抗体症候群 Primary antiphospholipid syndrome Clinical trials / Disease details
臨床試験数 : 5 / 薬物数 : 6 - (DrugBank : 4) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05671757 (ClinicalTrials.gov) | March 12, 2023 | 20/12/2022 | Daratumumab in Primary Antiphospholipid Syndrome | Targeting CD38 With Daratumumab in Primary Antiphospholipid Syndrome: A Phase 1b Dose Escalation Safety Trial (ITN093AI) | Autoimmune Disorders | Biological: Daratumumab | National Institute of Allergy and Infectious Diseases (NIAID) | Immune Tolerance Network (ITN);PPD;Rho Federal Systems Division, Inc. | Not yet recruiting | 18 Years | 65 Years | All | 22 | Phase 1/Phase 2 | United States |
| 2 | NCT05078710 (ClinicalTrials.gov) | July 1, 2021 | 24/9/2021 | Telitacicept in Primary APS Patients | A Pilot Study of Telitacicept Treatment in Primary APS Patients | Anti Phospholipid Syndrome | Drug: Telitacicept | Peking Union Medical College Hospital | NULL | Recruiting | 18 Years | 65 Years | All | 20 | Phase 2 | China |
| 3 | NCT03540810 (ClinicalTrials.gov) | August 15, 2018 | 27/4/2018 | Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome | Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome | Primary Antiphospholipid Syndrome | Drug: Hydroxychloroquine;Drug: Placebo | University Hospital, Angers | NULL | Not yet recruiting | 18 Years | N/A | All | 300 | Phase 3 | France |
| 4 | NCT01956188 (ClinicalTrials.gov) | May 2014 | 25/9/2013 | Omega 3 in LES and APS | Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome | Systemic Lupus Erythematosus;Primary Antiphospholipid Syndrome | Dietary Supplement: EPA and DHA supplementation;Dietary Supplement: Placebo | University of Sao Paulo | NULL | Active, not recruiting | 20 Years | 45 Years | Female | 22 | N/A | Brazil |
| 5 | NCT04153201 (ClinicalTrials.gov) | January 15, 2013 | 21/10/2019 | Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome | Effect of Hydroxychloroquine on Thrombosis Prevention and Antiphospholipid Antibody Levels in Patients With Primary Antiphospholipid Syndrome: An Pilot Randomized Prospective Study. | Antiphospholipid Syndrome | Drug: Hydroxychloroquine | National and Kapodistrian University of Athens | NULL | Completed | 18 Years | N/A | All | 50 | N/A | Greece |